All In Biotech

Drug Trial Radar · NCT01632241

Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)

A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race With Systemic Lupus Erythematosus (SLE)

Last checked: Nov 20, 2026Latest source record: Sep 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 503 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

503

Actual

Start

Feb 19, 2013

Primary completion

Jun 18, 2018

Study completion Jan 28, 2019

Sponsor

Sponsor type
Industry
Collaborators
GlaxoSmithKline
First posted
Jul 2, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety, and tolerability of belimumab in adult patients of black race with systemic lupus erythematosus (SLE; lupus).

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • Placebo plus standard therapyBiological

    Placebo plus standard therapy

  • Belimumab 10 mg/kg plus standard therapyBiological

    Belimumab 10mg/kg plus standard therapy

  • Standard therapyDrug

    Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index (SRI) Response Rate With the Modified Systemic Lupus Erythematosus Disease Activity Index- 2K (SLEDAI-2K) Scoring for Proteinuria at Week 52 [DB Phase]Time frame: Week 52
  2. Percentage of Participants Achieving a SRI Response Rate With the Modified SLEDAI-2K Scoring for Proteinuria at Week 24 of OL PhaseTime frame: Week 24 of OL phase (Week 76)
  3. Number of Participants With Non-serious Adverse Events (nSAEs) and Serious Adverse Event (SAEs) [OL Phase]Time frame: Week 52 to Week 84
  4. Number of Participants With Severe AEs [OL Phase]Time frame: Week 52 to Week 84
  5. Number of Participants With AEs Leading to Treatment Discontinuation [OL Phase]Time frame: Week 52 to Week 84
  6. Number of Participants With Worst Toxicity Grade 3 or 4 for Hematology Parameters [OL Phase]Time frame: Week 52 to Week 84
  7. Number of Participants With Worst Toxicity Grade of 3 or 4 for Clinical Chemistry Parameters [OL Phase]Time frame: Week 52 to Week 84
  8. Number of Participants With Worst Toxicity Grade of 3 or 4 for Urinalysis Parameters [OL Phase]Time frame: Week 52 to Week 84
  9. Number of Participants With Worst Toxicity Grade of 3 or 4 of Immunoglobulins [OL Phase]Time frame: Week 52 to Week 84

Locations

96 sites in 6 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Covina, California

  • GSK Investigational Site

    La Palma, California

  • GSK Investigational Site

    Lakewood, California

  • GSK Investigational Site

    Los Alamitos, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Murrieta, California

  • GSK Investigational Site

    Upland, California

  • GSK Investigational Site

    Bridgeport, Connecticut

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Aventura, Florida

  • GSK Investigational Site

    DeBary, Florida

  • GSK Investigational Site

    Fort Lauderdale, Florida

  • GSK Investigational Site

    Longwood, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami Lakes, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Plantation, Florida

  • GSK Investigational Site

    Tamarac, Florida

  • GSK Investigational Site

    Tampa, Florida

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    Duluth, Georgia

  • GSK Investigational Site

    Chicago, Illinois

  • GSK Investigational Site

    Baton Rouge, Louisiana

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Detroit, Michigan

  • GSK Investigational Site

    Lansing, Michigan

  • GSK Investigational Site

    Jackson, Mississippi

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Las Vegas, Nevada

  • GSK Investigational Site

    Las Vegas, Nevada

  • GSK Investigational Site

    Clifton, New Jersey

  • GSK Investigational Site

    Brooklyn, New York

  • GSK Investigational Site

    Brooklyn, New York

  • GSK Investigational Site

    Brooklyn, New York

  • GSK Investigational Site

    Great Neck, New York

  • GSK Investigational Site

    Manhasset, New York

  • GSK Investigational Site

    New York, New York

Showing 40 of 96 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.